ANI Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:BSFA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
17 Dec 24	Sell€398,550	Stephen Carey	Individual	7,500	€53.14
26 Nov 24	Sell€193,810	Nikhil Lalwani	Individual	3,481	€55.68
15 Nov 24	Sell€355,510	Christopher Mutz	Individual	6,500	€54.69
05 Jun 24	Sell€184,055	Ori Gutwerg	Individual	2,985	€61.66
04 Jun 24	Sell€292,150	Stephen Carey	Individual	5,000	€58.43
21 May 24	Sell€113,486	Christopher Mutz	Individual	2,000	€56.74
16 May 24	Sell€117,521	Renee Tannenbaum	Individual	2,000	€58.76
14 May 24	Sell€1,018,523	Nikhil Lalwani	Individual	16,669	€61.10
12 Mar 24	Sell€4,563,701	MVP Capital Partners	Company	75,000	€61.82
11 Mar 24	Sell€467,102	Stephen Carey	Individual	7,787	€59.98
08 Mar 24	Sell€2,733,006	Nikhil Lalwani	Individual	45,257	€61.33
07 Mar 24	Sell€1,478,011	James Marken	Individual	24,338	€60.73
05 Mar 24	Sell€303,666	Christopher Mutz	Individual	5,000	€60.73
04 Mar 24	Sell€420,207	Antonio Pera	Individual	7,000	€60.03

Insider Trading Volume

Insider Buying: BSFA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of BSFA?
Owner Type	Number of Shares	Ownership Percentage
State or Government	8,144	0.0354%
Private Companies	637,620	2.77%
VC/PE Firms	1,419,381	6.16%
Individual Insiders	1,525,071	6.62%
Institutions	19,437,558	84.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.

Top Shareholders

Top 25 shareholders own 79.87% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
13.8%	BlackRock, Inc.	2,689,712	€141.4m	1.25%	no data
7.27%	MVP Capital Partners	1,419,381	€74.6m	0%	100.0%
6.9%	The Vanguard Group, Inc.	1,348,111	€70.9m	-6.41%	no data
3.6%	State Street Global Advisors, Inc.	703,843	€37.0m	9.1%	no data
3.54%	Goldman Sachs Group, Investment Banking and Securities Investments	691,566	€36.4m	1,600%	0.02%
3.36%	Dimensional Fund Advisors LP	655,310	€34.5m	3.98%	0.01%
3.24%	Esjay Llc	632,620	€33.3m	-7.32%	no data
3.02%	Ranger Investment Management, L.P.	589,688	€31.0m	46.4%	1.99%
2.91%	Pacer Advisors, Inc.	568,343	€29.9m	23,300%	0.07%
2.75%	Global Alpha Capital Management Ltd.	536,450	€28.2m	1.8%	0.8%
2.71%	Citadel Advisors LLC	529,877	€27.9m	43.9%	0.03%
2.71%	Millennium Management LLC	529,752	€27.9m	130%	0.02%
2.59%	Deep Track Capital, LP	504,828	€26.5m	8.31%	0.86%
2.52%	Macquarie Investment Management Business Trust	491,647	€25.8m	26.7%	0.03%
2.43%	William Blair Investment Management, LLC	474,828	€25.0m	-2.97%	0.03%
2.3%	Tang Capital Management, LLC	450,000	€23.7m	0%	1.77%
2.18%	Geode Capital Management, LLC	425,225	€22.4m	4.24%	no data
1.9%	Nikhil Lalwani	370,378	€19.5m	-0.93%	no data
1.8%	JPMorgan Chase & Co, Brokerage and Securities Investments	350,669	€18.4m	934%	0.01%
1.64%	UBS Asset Management AG	320,439	€16.8m	328%	no data
1.56%	Morgan Stanley, Investment Banking and Brokerage Investments	303,843	€16.0m	74.8%	no data
1.38%	Soleus Capital Management, L.P.	269,000	€14.1m	0%	1.13%
1.28%	Charles Schwab Investment Management, Inc.	250,346	€13.2m	3.67%	no data
1.26%	Renaissance Technologies LLC	245,102	€12.9m	56.3%	0.02%
1.24%	Chad Gassert	242,905	€12.8m	-7.61%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 20:34
End of Day Share Price	2024/12/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ANI Pharmaceuticals, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dewey Steadman	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.
Timothy Chiang	Capital One Securities, Inc.